Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,931,139

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $102.37 -0.21 (-0.20%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (202 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates

Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.

Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips

Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.

Shockwave Medical's (SWAV) Q4 Earnings Top, Revenues Surge Y/Y

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down

QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall

The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.

Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay

Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.

West Pharmaceutical (WST) Q4 Earnings Beat, Order Book Strong

West Pharmaceutical's (WST) fourth-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.

Here's Why You Should Add Cooper Companies (COO) Stock Now

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Sweta Killa headshot

5 Dividend Growth Stocks to Buy Amid Market Volatility

Microchip Technology (MCHP), Caterpillar (CAT), Xcel Energy (XEL), Cardinal Health (CAH) and Archer-Daniels-Midland (ADM) could be compelling dividend growth picks amid market volatility.

Quest Diagnostics (DGX) New Pact to Boost Laboratory Services

Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.

Thermo Fisher (TMO) Rides on Strong End Markets, New Launches

Thermo Fisher's (TMO) newly-launched Gibco CTS DynaCellect Magnetic Separation System is helping customers advance their cell and gene therapy programs.

Ecolab (ECL) Q4 Earnings & Revenues Beat, Margins Decline

Ecolab's (ECL) robust performance across all segments drives its Q4 sales despite business challenges.

PerkinElmer's (PKI) Q4 Earnings Top, Revenues Decline Y/Y

PerkinElmer's (PKI) fourth-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, more than offset by lower COVID-related sales.

Charles River (CRL) Introduces Novel IgY-Based ELISA Kit

Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.

ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers

ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA) on continued partnership growth and a strong focus on strategic execution.

Abbott (ABT) to Expand Vascular Device Line With New Buyout

Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges

At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.

BD's (BDX) Latest Combination Test Receives the FDA's EUA

BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.

Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss

With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.